News
SONN
1.460
+2.82%
0.040
SONNET BIOTHERAPEUTICS ANNOUNCES RELEASE OF THE NEXT CEO CORNER SEGMENT
Reuters · 3d ago
Weekly Report: what happened at SONN last week (1216-1220)?
Weekly Report · 3d ago
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 6d ago
Sonnet BioTherapeutics Price Target Cut to $20.00/Share From $30.00 by Chardan Capital
Dow Jones · 6d ago
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20
Benzinga · 6d ago
Based on the provided financial report articles, I generated the title for the article: "Sonnet BioTherapeutics Holdings, Inc. (SONN) Reports Financial Results for the Fiscal Year Ended September 30, 2024" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be related to the financial results of Sonnet BioTherapeutics Holdings, Inc. (SONN) for the fiscal year ended September 30, 2024.
Press release · 12/17 20:31
Sonnet BioTherapeutics Holdings, Inc. Reports Significant Clinical Progress and Financial Updates for Fiscal Year 2024
Barchart · 12/17 18:12
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 12/17 14:27
Insights into Sonnet BioTherapeutics Q4 Earnings
Benzinga · 12/17 14:25
Sonnet BioTherapeutics GAAP EPS of -$11.35
Seeking Alpha · 12/17 14:01
Sonnet BioTherapeutics reports FY24 EPS ($11.35) vs. ($145.13) last year
TipRanks · 12/17 13:55
Sonnet BioTherapeutics sees cash runway into July 2025
TipRanks · 12/17 13:55
Sonnet BioTherapeutics FY 2024 GAAP EPS $(11.35)
Benzinga · 12/17 13:53
SONNET BIOTHERAPEUTICS REPORTS FISCAL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 12/17 13:50
Weekly Report: what happened at SONN last week (1209-1213)?
Weekly Report · 12/16 12:25
Sonnet Biotherapeutics Holdings Inc <SONN.OQ> expected to post a loss of $5.52 a share - Earnings Preview
Reuters · 12/13 21:03
Sonnet Biotherapeutics Holdings Inc <SONN.OQ> expected to post a loss of $5.52 a share - Earnings Preview
Reuters · 12/10 21:02
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/09 21:05
Sonnet BioTherapeutics announces $3.9M registered direct offering
TipRanks · 12/09 20:45
SONNET BIOTHERAPEUTICS ANNOUNCES $3.9 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 12/09 20:42
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.